{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:23:17Z","timestamp":1792700597420,"version":"4.5.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11154-023-09787-4","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T06:08:17Z","timestamp":1675058897000},"page":"327-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond"],"prefix":"10.1007","volume":"24","author":[{"given":"Wei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-5759","authenticated-orcid":false,"given":"Jidong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"9787_CR1","doi-asserted-by":"crossref","unstructured":"Chen Y, Luo L, Hu S et al. The chemistry, processing, and preclinical anti-hyperuricemia potential of tea: a comprehensive review. Crit Rev Food Sci Nutr.\u00a02022:1\u201326.","DOI":"10.1080\/10408398.2022.2040417"},{"key":"9787_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10067-012-2108-z","volume":"32","author":"L Liu","year":"2013","unstructured":"Liu L, Lou S, Xu K, et al. Relationship between lifestyle choices and hyperuricemia in chinese men and women. Clin Rheumatol. 2013;32:233\u20139.","journal-title":"Clin Rheumatol"},{"key":"9787_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3904\/kjim.2020.116","volume":"36","author":"BS Koo","year":"2021","unstructured":"Koo BS, Jeong HJ, Son CN, et al. Distribution of serum uric acid levels and prevalence of hyper- and hypouricemia in a korean general population of 172,970. Korean J Intern Med. 2021;36:S264\u201372.","journal-title":"Korean J Intern Med"},{"key":"9787_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s41256-020-00178-9","volume":"5","author":"J Huang","year":"2020","unstructured":"Huang J, Ma ZF, Zhang Y, et al. Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis. Glob Health Res Policy. 2020;5:52.","journal-title":"Glob Health Res Policy"},{"key":"9787_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and Decadal Trends: the National Health and Nutrition Examination Survey, 2007\u20132016. Arthritis Rheumatol. 2019;71:991\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"9787_CR6","doi-asserted-by":"publisher","first-page":"e0240402","DOI":"10.1371\/journal.pone.0240402","volume":"15","author":"T Sofue","year":"2020","unstructured":"Sofue T, Nakagawa N, Kanda E, et al. Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan chronic kidney Disease Database (J-CKD-DB). PLoS ONE. 2020;15:e0240402.","journal-title":"PLoS ONE"},{"key":"9787_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.arcmed.2006.03.008","volume":"37","author":"V Lohsoonthorn","year":"2006","unstructured":"Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in thai adults receiving annual health exams. Arch Med Res. 2006;37:883\u20139.","journal-title":"Arch Med Res"},{"key":"9787_CR8","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout Lancet. 2021;397:1843\u201355.","journal-title":"Gout Lancet"},{"key":"9787_CR9","doi-asserted-by":"crossref","unstructured":"Yu W, Cheng JD. Uric acid and cardiovascular disease: An update from molecular mechanism to clinical perspective. Front Pharmacol. 2020;11:582680.","DOI":"10.3389\/fphar.2020.582680"},{"key":"9787_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","volume":"71","author":"RJ Johnson","year":"2018","unstructured":"Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71:851\u201365.","journal-title":"Am J Kidney Dis"},{"key":"9787_CR11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.kint.2020.05.056","volume":"98","author":"C Ponticelli","year":"2020","unstructured":"Ponticelli C, Podest\u00e0 MA, Moroni G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. Kidney Int. 2020;98:1149\u201359.","journal-title":"Kidney Int"},{"key":"9787_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380\u201390.","journal-title":"Nat Rev Rheumatol"},{"key":"9787_CR13","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/annrheumdis-2017-211472","volume":"76","author":"SM Nielsen","year":"2017","unstructured":"Nielsen SM, Bartels EM, Henriksen M, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017;76:1870\u201382.","journal-title":"Ann Rheum Dis"},{"key":"9787_CR14","doi-asserted-by":"crossref","unstructured":"Kim K, Kang K, Sheol H et al. The association between serum uric acid levels and 10-year cardiovascular disease risk in non-alcoholic fatty liver disease patients. Int J Environ Res Public Health. 2022;19:1042.","DOI":"10.3390\/ijerph19031042"},{"key":"9787_CR15","doi-asserted-by":"publisher","first-page":"E1032","DOI":"10.1152\/ajpendo.00518.2020","volume":"320","author":"D Xie","year":"2021","unstructured":"Xie D, Zhao H, Lu J, et al. High uric acid induces liver fat accumulation via ROS\/JNK\/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320:E1032\u201343.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"9787_CR16","doi-asserted-by":"publisher","first-page":"657856","DOI":"10.3389\/fendo.2021.657856","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Ma X, Xing J, et al. Serum uric acid is a mediator of the association between obesity and incident nonalcoholic fatty liver disease: a prospective cohort study. Front Endocrinol (Lausanne). 2021;12:657856.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9787_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/brain\/awn316","volume":"132","author":"SM Euser","year":"2009","unstructured":"Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain. 2009;132:377\u201382.","journal-title":"Brain"},{"key":"9787_CR18","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00702-016-1622-6","volume":"123","author":"MT Pellecchia","year":"2016","unstructured":"Pellecchia MT, Savastano R, Moccia M, et al. Lower serum uric acid is associated with mild cognitive impairment in early Parkinson\u2019s disease: a 4-year follow-up study. J Neural Transm (Vienna). 2016;123:1399\u2013402.","journal-title":"J Neural Transm (Vienna)"},{"key":"9787_CR19","doi-asserted-by":"publisher","first-page":"747686","DOI":"10.3389\/fnagi.2021.747686","volume":"13","author":"C Chen","year":"2021","unstructured":"Chen C, Li X, Lv Y, et al. High blood uric acid is associated with reduced risks of mild cognitive impairment among older adults in China: a 9-Year prospective cohort study. Front Aging Neurosci. 2021;13:747686.","journal-title":"Front Aging Neurosci"},{"key":"9787_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbrc.2020.12.097","volume":"540","author":"Q Wang","year":"2021","unstructured":"Wang Q, Zhao H, Gao Y, et al. Uric acid inhibits HMGB1-TLR4-NF-kappaB signaling to alleviate oxygen-glucose deprivation\/reoxygenation injury of microglia. Biochem Biophys Res Commun. 2021;540:22\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"9787_CR21","doi-asserted-by":"publisher","first-page":"116866","DOI":"10.1016\/j.jns.2020.116866","volume":"414","author":"AB Alam","year":"2020","unstructured":"Alam AB, Wu A, Power MC, et al. Associations of serum uric acid with incident dementia and cognitive decline in the ARIC-NCS cohort. J Neurol Sci. 2020;414:116866.","journal-title":"J Neurol Sci"},{"key":"9787_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/annrheumdis-2016-210767","volume":"77","author":"A Latourte","year":"2018","unstructured":"Latourte A, Soumar\u00e9 A, Bardin T, et al. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis. 2018;77:328\u201335.","journal-title":"Ann Rheum Dis"},{"key":"9787_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415\u201328.","journal-title":"Lancet"},{"key":"9787_CR24","doi-asserted-by":"crossref","unstructured":"Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am. 2007;91:1063\u201377.","DOI":"10.1016\/j.mcna.2007.06.012"},{"key":"9787_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/aje\/kws002","volume":"176","author":"E Krishnan","year":"2012","unstructured":"Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol. 2012;176:108\u201316.","journal-title":"Am J Epidemiol"},{"key":"9787_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1161\/HYPERTENSIONAHA.117.09508","volume":"70","author":"T Han","year":"2017","unstructured":"Han T, Lan L, Qu R, et al. Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension. Hypertension. 2017;70:703\u201311.","journal-title":"Hypertension"},{"key":"9787_CR27","first-page":"25","volume":"78","author":"H Vuorinen-Markkola","year":"1994","unstructured":"Vuorinen-Markkola H, Yki-J\u00e4rvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"9787_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","volume":"63","author":"M Takir","year":"2015","unstructured":"Takir M, Kostek O, Ozkok A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63:924\u20139.","journal-title":"J Investig Med"},{"key":"9787_CR29","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/art.41779","volume":"73","author":"N McCormick","year":"2021","unstructured":"McCormick N, O\u2019Connor MJ, Yokose C, et al. Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional mendelian randomization. Arthritis Rheumatol. 2021;73:2096\u2013104.","journal-title":"Arthritis Rheumatol"},{"key":"9787_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41584-019-0222-x","volume":"15","author":"J Lu","year":"2019","unstructured":"Lu J, Dalbeth N, Yin H, et al. Mouse models for human hyperuricaemia: a critical review. Nat Rev Rheumatol. 2019;15:413\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"9787_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.kint.2017.04.031","volume":"93","author":"J Lu","year":"2018","unstructured":"Lu J, Hou X, Yuan X, et al. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders. Kidney Int. 2018;93:69\u201380.","journal-title":"Kidney Int"},{"key":"9787_CR32","first-page":"1","volume":"36","author":"Chinese Society of Endocrinology, Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Endocrinology, Chinese Medical Association. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019). Chin J Endocrinol Metab. 2020;36:1\u201313.","journal-title":"Chin J Endocrinol Metab"},{"key":"9787_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1166\/jbn.2019.2752","volume":"15","author":"Y Hao","year":"2019","unstructured":"Hao Y, Li H, Cao Y, et al. Uricase and horseradish peroxidase hybrid CaHPO(4) nanoflower integrated with transcutaneous patches for treatment of hyperuricemia. J Biomed Nanotechnol. 2019;15:951\u201365.","journal-title":"J Biomed Nanotechnol"},{"key":"9787_CR34","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","volume":"69","author":"M Kuwabara","year":"2017","unstructured":"Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension. 2017;69:1036\u201344.","journal-title":"Hypertension"},{"key":"9787_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2018.03.045","volume":"261","author":"M Kuwabara","year":"2018","unstructured":"Kuwabara M, Borghi C, Cicero AFG, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol. 2018;261:183\u20138.","journal-title":"Int J Cardiol"},{"key":"9787_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1161\/HYPERTENSIONAHA.117.10370","volume":"71","author":"M Kuwabara","year":"2018","unstructured":"Kuwabara M, Hisatome I, Niwa K, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension. 2018;71:78\u201386.","journal-title":"Hypertension"},{"key":"9787_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2018.10.007","volume":"278","author":"T Maruhashi","year":"2018","unstructured":"Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis. 2018;278:226\u201331.","journal-title":"Atherosclerosis"},{"key":"9787_CR38","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1111\/jocd.13401","volume":"19","author":"J Ma","year":"2020","unstructured":"Ma J, Sheng Y, Lao Z, et al. Hyperuricemia is associated with androgenetic alopecia in men: a cross-sectional case-control study. J Cosmet Dermatol. 2020;19:3122\u20136.","journal-title":"J Cosmet Dermatol"},{"key":"9787_CR39","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/jsm.12495","volume":"11","author":"S Salem","year":"2014","unstructured":"Salem S, Mehrsai A, Heydari R, Pourmand G. Serum uric acid as a risk predictor for erectile dysfunction. J Sex Med. 2014;11:1118\u201324.","journal-title":"J Sex Med"},{"key":"9787_CR40","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3899\/jrheum.141105","volume":"42","author":"YF Chen","year":"2015","unstructured":"Chen YF, Lin HH, Lu CC, et al. Gout and a subsequent increased risk of erectile dysfunction in men aged 64 and under: a nationwide cohort study in Taiwan. J Rheumatol. 2015;42:1898\u2013905.","journal-title":"J Rheumatol"},{"key":"9787_CR41","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jsxm.2016.04.073","volume":"13","author":"H Long","year":"2016","unstructured":"Long H, Jiang J, Xia J, et al. Hyperuricemia is an independent risk factor for erectile dysfunction. J Sex Med. 2016;13:1056\u201362.","journal-title":"J Sex Med"},{"key":"9787_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13075-017-1322-0","volume":"19","author":"A Abdul Sultan","year":"2017","unstructured":"Abdul Sultan A, Mallen C, Hayward R, et al. Gout and subsequent erectile dysfunction: a population-based cohort study from England. Arthritis Res Ther. 2017;19:123.","journal-title":"Arthritis Res Ther"},{"key":"9787_CR43","doi-asserted-by":"crossref","unstructured":"Wang W, Jing Z, Liu W et al. Hyperuricaemia is an important risk factor of the erectile dysfunction: A systematic review and meta-analysis. Andrologia.\u00a02022:e14384.","DOI":"10.1111\/and.14384"},{"key":"9787_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/andr.13088","volume":"10","author":"M Totaro","year":"2022","unstructured":"Totaro M, Dimarakis S, Castellini C, et al. Erectile dysfunction in hyperuricemia: a prevalence meta-analysis and meta-regression study. Andrology. 2022;10:72\u201381.","journal-title":"Andrology"},{"key":"9787_CR45","doi-asserted-by":"publisher","first-page":"154766","DOI":"10.1016\/j.metabol.2021.154766","volume":"119","author":"MA Hill","year":"2021","unstructured":"Hill MA, Yang Y, Zhang L, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119:154766.","journal-title":"Metabolism"},{"key":"9787_CR46","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s00125-011-2127-3","volume":"54","author":"C Lipina","year":"2011","unstructured":"Lipina C, Hundal HS. Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance. Diabetologia. 2011;54:1596\u2013607.","journal-title":"Diabetologia"},{"key":"9787_CR47","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1002\/jcp.27603","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. 2019;234:8152\u201361.","journal-title":"J Cell Physiol"},{"key":"9787_CR48","doi-asserted-by":"crossref","unstructured":"Saltiel AR. Insulin signaling in health and disease. J Clin Invest. 2021;131:e142241.","DOI":"10.1172\/JCI142241"},{"key":"9787_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41580-018-0044-8","volume":"19","author":"Q Yang","year":"2018","unstructured":"Yang Q, Vijayakumar A, Kahn BB. Metabolites as regulators of insulin sensitivity and metabolism. Nat Rev Mol Cell Biol. 2018;19:654\u201372.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9787_CR50","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","volume":"148","author":"VT Samuel","year":"2012","unstructured":"Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148:852\u201371.","journal-title":"Cell"},{"key":"9787_CR51","doi-asserted-by":"publisher","first-page":"e2547","DOI":"10.1210\/clinem\/dgab200","volume":"106","author":"J Zhu","year":"2021","unstructured":"Zhu J, Sun L, Yang J, et al. Genetic predisposition to type 2 diabetes and insulin levels is positively associated with serum urate levels. J Clin Endocrinol Metab. 2021;106:e2547-56.","journal-title":"J Clin Endocrinol Metab"},{"key":"9787_CR52","doi-asserted-by":"publisher","first-page":"108542","DOI":"10.1016\/j.diabres.2020.108542","volume":"171","author":"X Hu","year":"2021","unstructured":"Hu X, Rong S, Wang Q, et al. Association between plasma uric acid and insulin resistance in type 2 diabetes: a mendelian randomization analysis. Diabetes Res Clin Pract. 2021;171:108542.","journal-title":"Diabetes Res Clin Pract"},{"key":"9787_CR53","doi-asserted-by":"publisher","first-page":"713710","DOI":"10.3389\/fphys.2021.713710","volume":"12","author":"AK Mandal","year":"2021","unstructured":"Mandal AK, Leask MP, Estiverne C, et al. Genetic and physiological effects of insulin on human urate homeostasis. Front Physiol. 2021;12:713710.","journal-title":"Front Physiol"},{"key":"9787_CR54","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41598-020-57784-3","volume":"10","author":"T Nishikawa","year":"2020","unstructured":"Nishikawa T, Nagata N, Shimakami T, et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep. 2020;10:815.","journal-title":"Sci Rep"},{"key":"9787_CR55","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/1440-1681.13574","volume":"48","author":"HY Ng","year":"2021","unstructured":"Ng HY, Leung FF, Kuo WH, et al. Dapagliflozin and xanthine oxidase inhibitors improve insulin resistance and modulate renal glucose and urate transport in metabolic syndrome. Clin Exp Pharmacol Physiol. 2021;48:1603\u201312.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"9787_CR56","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.bmcl.2004.12.003","volume":"15","author":"B Rocic","year":"2005","unstructured":"Rocic B, Vucic-Lovrencic M, Poje N, et al. Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells. Bioorg Med Chem Lett. 2005;15:1181\u20134.","journal-title":"Bioorg Med Chem Lett"},{"key":"9787_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mce.2013.04.027","volume":"375","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yamamoto T, Hisatome I, et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic beta cells. Mol Cell Endocrinol. 2013;375:89\u201396.","journal-title":"Mol Cell Endocrinol"},{"key":"9787_CR58","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2337\/db19-0704","volume":"69","author":"J Lu","year":"2020","unstructured":"Lu J, He Y, Cui L, et al. Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic beta-cell death in uricase-deficient male mice. Diabetes. 2020;69:1149\u201363.","journal-title":"Diabetes"},{"key":"9787_CR59","doi-asserted-by":"publisher","first-page":"111070","DOI":"10.1016\/j.mce.2020.111070","volume":"520","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhao H, Lu J, et al. High uric acid promotes dysfunction in pancreatic beta cells by blocking IRS2\/AKT signalling. Mol Cell Endocrinol. 2021;520:111070.","journal-title":"Mol Cell Endocrinol"},{"key":"9787_CR60","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2014.04.080","volume":"447","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Hu Y, Huang T, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun. 2014;447:707\u201314.","journal-title":"Biochem Biophys Res Commun"},{"key":"9787_CR61","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.mce.2016.12.025","volume":"443","author":"H Yuan","year":"2017","unstructured":"Yuan H, Hu Y, Zhu Y, et al. Metformin ameliorates high uric acid-induced insulin resistance in skeletal muscle cells. Mol Cell Endocrinol. 2017;443:138\u201345.","journal-title":"Mol Cell Endocrinol"},{"key":"9787_CR62","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2337\/db10-0916","volume":"60","author":"W Baldwin","year":"2011","unstructured":"Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258\u201369.","journal-title":"Diabetes"},{"key":"9787_CR63","doi-asserted-by":"publisher","first-page":"653819","DOI":"10.3389\/fendo.2021.653819","volume":"12","author":"C Liu","year":"2021","unstructured":"Liu C, Zhou XR, Ye MY, et al. RBP4 is associated with insulin resistance in hyperuricemia-induced rats and patients with hyperuricemia. Front Endocrinol (Lausanne). 2021;12:653819.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9787_CR64","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","volume":"64","author":"X Wan","year":"2016","unstructured":"Wan X, Xu C, Lin Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925\u201332.","journal-title":"J Hepatol"},{"key":"9787_CR65","doi-asserted-by":"publisher","first-page":"111599","DOI":"10.1016\/j.mce.2022.111599","volume":"547","author":"F He","year":"2022","unstructured":"He F, Wang M, Zhao H, et al. Autophagy protects against high uric acid-induced hepatic insulin resistance. Mol Cell Endocrinol. 2022;547:111599.","journal-title":"Mol Cell Endocrinol"},{"key":"9787_CR66","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.molmet.2021.101411","volume":"55","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Nagoshi T, Takahashi H, et al. URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice. Mol Metab. 2022;55:101411.","journal-title":"Mol Metab"},{"key":"9787_CR67","doi-asserted-by":"publisher","first-page":"e0147737","DOI":"10.1371\/journal.pone.0147737","volume":"11","author":"L Zhi","year":"2016","unstructured":"Zhi L, Yuzhang Z, Tianliang H, et al. High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo. PLoS ONE. 2016;11:e0147737.","journal-title":"PLoS ONE"},{"key":"9787_CR68","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1111\/jcmm.16677","volume":"25","author":"Z Jiao","year":"2021","unstructured":"Jiao Z, Chen Y, Xie Y, et al. Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. J Cell Mol Med. 2021;25:6733\u201345.","journal-title":"J Cell Mol Med"},{"key":"9787_CR69","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1096\/fj.13-247148","volume":"28","author":"YJ Choi","year":"2014","unstructured":"Choi YJ, Yoon Y, Lee KY, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28:3197\u2013204.","journal-title":"FASEB J"},{"key":"9787_CR70","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fendo.2018.00098","volume":"9","author":"EJ Tassone","year":"2018","unstructured":"Tassone EJ, Cimellaro A, Perticone M, et al. Uric acid impairs insulin signaling by promoting Enpp1 binding to insulin receptor in human umbilical vein endothelial cells. Front Endocrinol (Lausanne). 2018;9:98.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9787_CR71","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2021.11.034","volume":"178","author":"W Yu","year":"2022","unstructured":"Yu W, Chen C, Zhuang W, et al. Silencing TXNIP ameliorates high uric acid-induced insulin resistance via the IRS2\/AKT and Nrf2\/HO-1 pathways in macrophages. Free Radic Biol Med. 2022;178:42\u201353.","journal-title":"Free Radic Biol Med"},{"key":"9787_CR72","doi-asserted-by":"publisher","first-page":"931087","DOI":"10.3389\/fimmu.2022.931087","volume":"13","author":"H Zhao","year":"2022","unstructured":"Zhao H, He F, Lu J, et al. Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway via IRS2-proteasome degradation. Front Immunol. 2022;13:931087.","journal-title":"Front Immunol"},{"key":"9787_CR73","doi-asserted-by":"publisher","first-page":"e3001","DOI":"10.1002\/dmrr.3001","volume":"34","author":"M Li","year":"2018","unstructured":"Li M, Gu L, Yang J, Lou Q. Serum uric acid to creatinine ratio correlates with \u03b2-cell function in type 2 diabetes. Diabetes Metab Res Rev. 2018;34:e3001.","journal-title":"Diabetes Metab Res Rev"},{"key":"9787_CR74","doi-asserted-by":"crossref","unstructured":"Tang W, Fu Q, Zhang Q et al. The association between serum uric acid and residual \u03b2 -cell function in type 2 diabetes. J Diabetes Res 2014;2014:709691.","DOI":"10.1155\/2014\/709691"},{"key":"9787_CR75","doi-asserted-by":"publisher","first-page":"e6666","DOI":"10.7717\/peerj.6666","volume":"7","author":"X Zhong","year":"2019","unstructured":"Zhong X, Zhang D, Yang L, et al. The relationship between serum uric acid within the normal range and \u03b2-cell function in chinese patients with type 2 diabetes: differences by body mass index and gender. PeerJ. 2019;7:e6666.","journal-title":"PeerJ"},{"key":"9787_CR76","doi-asserted-by":"publisher","first-page":"590","DOI":"10.5414\/CP203513","volume":"57","author":"E Kutoh","year":"2019","unstructured":"Kutoh E, Wada A, Kuto AN, Hayashi J. Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: a potential link between uric acid and pancreatic \u03b2-cell function. Int J Clin Pharmacol Ther. 2019;57:590\u20135.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9787_CR77","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2147\/DMSO.S312489","volume":"14","author":"P Yu","year":"2021","unstructured":"Yu P, Huang L, Wang Z, et al. The Association of serum uric acid with Beta-cell function and insulin resistance in nondiabetic individuals: a cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:2673\u201382.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"9787_CR78","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pcd.2020.10.006","volume":"15","author":"FD Martinez-Sanchez","year":"2021","unstructured":"Martinez-Sanchez FD, Vargas-Abonce VP, Guerrero-Castillo AP, et al. Serum uric acid concentration is associated with insulin resistance and impaired insulin secretion in adults at risk for type 2 diabetes. Prim Care Diabetes. 2021;15:293\u20139.","journal-title":"Prim Care Diabetes"},{"key":"9787_CR79","doi-asserted-by":"crossref","unstructured":"Fernandez-Chirino L, Antonio-Villa NE, Fermin-Martinez CA et al. Elevated serum uric acid is a facilitating mechanism for insulin resistance mediated accumulation of visceral adipose tissue. Clin Endocrinol (Oxf). 2022;96:707\u201318.","DOI":"10.1111\/cen.14673"},{"key":"9787_CR80","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40:1367\u201393.","journal-title":"Endocr Rev"},{"issue":"Suppl 1","key":"9787_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1262-3636(08)70096-X","volume":"34","author":"D Feuvray","year":"2008","unstructured":"Feuvray D, Darmellah A. Diabetes-related metabolic perturbations in cardiac myocyte. Diabetes Metab. 2008;34(Suppl 1):3\u20139.","journal-title":"Diabetes Metab"},{"key":"9787_CR82","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/MCO.0b013e328042ba90","volume":"10","author":"J Delarue","year":"2007","unstructured":"Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care. 2007;10:142\u20138.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"9787_CR83","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.amjcard.2014.09.008","volume":"114","author":"M Vaduganathan","year":"2014","unstructured":"Vaduganathan M, Greene SJ, Ambrosy AP, et al. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014;114:1713\u201321.","journal-title":"Am J Cardiol"},{"key":"9787_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","volume":"16","author":"H Huang","year":"2014","unstructured":"Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16:15\u201324.","journal-title":"Eur J Heart Fail"},{"key":"9787_CR85","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.amjcard.2017.06.057","volume":"120","author":"A Palazzuoli","year":"2017","unstructured":"Palazzuoli A, Ruocco G, De Vivo O, et al. Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction. Am J Cardiol. 2017;120:1146\u201350.","journal-title":"Am J Cardiol"},{"key":"9787_CR86","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/clc.23197","volume":"42","author":"M Pavlusova","year":"2019","unstructured":"Pavlusova M, Jarkovsky J, Benesova K, et al. Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry. Clin Cardiol. 2019;42:720\u20137.","journal-title":"Clin Cardiol"},{"key":"9787_CR87","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"9787_CR88","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"9787_CR89","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819\u201329.","journal-title":"Lancet"},{"key":"9787_CR90","doi-asserted-by":"crossref","unstructured":"Wilcox CS, Shen W, Boulton DW et al. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc. 2018;7:e007046.","DOI":"10.1161\/JAHA.117.007046"},{"key":"9787_CR91","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13101","volume":"20","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:458\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"9787_CR92","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.sjbs.2018.11.013","volume":"26","author":"Y Xin","year":"2019","unstructured":"Xin Y, Guo Y, Li Y, et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: a systematic review with an indirect comparison meta-analysis. Saudi J Biol Sci. 2019;26:421\u20136.","journal-title":"Saudi J Biol Sci"},{"key":"9787_CR93","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223\u201333.","journal-title":"Lancet"},{"key":"9787_CR94","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.jacc.2021.02.057","volume":"77","author":"H Honka","year":"2021","unstructured":"Honka H, Solis-Herrera C, Triplitt C, et al. Therapeutic manipulation of myocardial metabolism: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:2022\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"9787_CR95","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","volume":"167","author":"JRB Dyck","year":"2022","unstructured":"Dyck JRB, Sossalla S, Hamdani N, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol. 2022;167:17\u201331.","journal-title":"J Mol Cell Cardiol"},{"key":"9787_CR96","doi-asserted-by":"crossref","unstructured":"Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107:1032\u20138.","DOI":"10.1136\/heartjnl-2020-318060"},{"key":"9787_CR97","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: a \u201cThrifty Substrate\u201d hypothesis. Diabetes Care. 2016;39:1108\u201314.","journal-title":"Diabetes Care"},{"key":"9787_CR98","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115\u201322.","journal-title":"Diabetes Care"},{"key":"9787_CR99","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018;15:335\u201346.","journal-title":"Redox Biol"},{"key":"9787_CR100","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","volume":"65","author":"SA Hawley","year":"2016","unstructured":"Hawley SA, Ford RJ, Smith BK, et al. The Na+\/Glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65:2784\u201394.","journal-title":"Diabetes"},{"key":"9787_CR101","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00424-021-02606-2","volume":"474","author":"Z Bahadoran","year":"2022","unstructured":"Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection. Pflugers Arch. 2022;474:83\u201398.","journal-title":"Pflugers Arch"},{"key":"9787_CR102","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"MA Gimbrone Jr","year":"2016","unstructured":"Gimbrone MA Jr, Garc\u00eda-Carde\u00f1a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620\u201336.","journal-title":"Circ Res"},{"key":"9787_CR103","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","volume":"73","author":"S Xu","year":"2021","unstructured":"Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73:924\u201367.","journal-title":"Pharmacol Rev"},{"key":"9787_CR104","doi-asserted-by":"crossref","unstructured":"Cassano V, Crescibene D, Hribal ML et al. Uric acid and vascular damage in essential hypertension: role of insulin resistance. Nutrients. 2020;12:2509.","DOI":"10.3390\/nu12092509"},{"key":"9787_CR105","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","volume":"145","author":"KJ Moore","year":"2011","unstructured":"Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341\u201355.","journal-title":"Cell"},{"key":"9787_CR106","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cmet.2011.07.015","volume":"14","author":"KE Bornfeldt","year":"2011","unstructured":"Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575\u201385.","journal-title":"Cell Metab"},{"key":"9787_CR107","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","volume":"53","author":"RA DeFronzo","year":"2010","unstructured":"DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links.\u00a0The Claude Bernard lecture 2009. Diabetologia. 2010;53:1270\u201387.","journal-title":"Diabetologia"},{"key":"9787_CR108","doi-asserted-by":"crossref","unstructured":"Mukhuty A, Fouzder C, Kundu R. Fetuin-A secretion from beta-cells leads to accumulation of macrophages in islets, aggravates inflammation and impairs insulin secretion. J Cell Sci. 2021;134:jcs258507.","DOI":"10.1242\/jcs.258507"},{"key":"9787_CR109","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12929-016-0303-y","volume":"23","author":"K Rehman","year":"2016","unstructured":"Rehman K, Akash MS. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci. 2016;23:87.","journal-title":"J Biomed Sci"},{"issue":"Suppl 3","key":"9787_CR110","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/dom.12161","volume":"15","author":"Y Imai","year":"2013","unstructured":"Imai Y, Dobrian AD, Weaver JR, et al. Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease. Diabetes Obes Metab. 2013;15(Suppl 3):117\u201329.","journal-title":"Diabetes Obes Metab"},{"key":"9787_CR111","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.tem.2013.01.007","volume":"24","author":"Y Imai","year":"2013","unstructured":"Imai Y, Dobrian AD, Morris MA, Nadler JL. Islet inflammation: a unifying target for diabetes treatment? Trends Endocrinol Metab. 2013;24:351\u201360.","journal-title":"Trends Endocrinol Metab"},{"key":"9787_CR112","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3389\/fcell.2020.00703","volume":"8","author":"M Chen","year":"2020","unstructured":"Chen M, Ye C, Zhu J, et al. Bergenin as a novel urate-lowering therapeutic strategy for hyperuricemia. Front Cell Dev Biol. 2020;8:703.","journal-title":"Front Cell Dev Biol"},{"key":"9787_CR113","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","volume":"44","author":"TA Wynn","year":"2016","unstructured":"Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44:450\u201362.","journal-title":"Immunity"},{"key":"9787_CR114","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1007\/s00018-015-1995-y","volume":"72","author":"A Sica","year":"2015","unstructured":"Sica A, Erreni M, Allavena P, Porta C. Macrophage polarization in pathology. Cell Mol Life Sci. 2015;72:4111\u201326.","journal-title":"Cell Mol Life Sci"},{"key":"9787_CR115","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nri3087","volume":"11","author":"A Chow","year":"2011","unstructured":"Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol. 2011;11:788\u201398.","journal-title":"Nat Rev Immunol"},{"key":"9787_CR116","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.tem.2020.12.001","volume":"32","author":"A Rehman","year":"2021","unstructured":"Rehman A, Pacher P, Hask\u00f3 G. Role of macrophages in the endocrine system. Trends Endocrinol Metab. 2021;32:238\u201356.","journal-title":"Trends Endocrinol Metab"},{"key":"9787_CR117","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fendo.2013.00093","volume":"4","author":"S Tateya","year":"2013","unstructured":"Tateya S, Kim F, Tamori Y. Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:93.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9787_CR118","doi-asserted-by":"crossref","unstructured":"Yu W, Liu W, Xie et al. High level of uric acid promotes atherosclerosis by targeting NRF2-mediated autophagy dysfunction and ferroptosis. Oxid Med Cell Longev.\u00a02022;2022:9304383.","DOI":"10.1155\/2022\/9304383"},{"key":"9787_CR119","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/ATVBAHA.119.313224","volume":"40","author":"Y Kimura","year":"2020","unstructured":"Kimura Y, Yanagida T, Onda A, et al. Soluble uric acid promotes atherosclerosis via AMPK (AMP-Activated protein Kinase)-Mediated inflammation. Arterioscler Thromb Vasc Biol. 2020;40:570\u201382.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9787_CR120","doi-asserted-by":"crossref","unstructured":"Qayyum N, Haseeb M, Kim MS, Choi S. Role of thioredoxin-interacting protein in diseases and its therapeutic outlook. Int J Mol Sci. 2021;22:275422.","DOI":"10.3390\/ijms22052754"},{"key":"9787_CR121","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cmet.2020.07.002","volume":"32","author":"LA Thielen","year":"2020","unstructured":"Thielen LA, Chen J, Jing G, et al. Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action. Cell Metab. 2020;32:353\u201365.","journal-title":"Cell Metab"},{"key":"9787_CR122","doi-asserted-by":"publisher","first-page":"113045","DOI":"10.1016\/j.fct.2022.113045","volume":"164","author":"W Zhang","year":"2022","unstructured":"Zhang W, Xu P, Li JY. The crucial role of thioredoxin interacting protein in the liver insulin resistance induced by di (2-ethylhexyl) phthalates. Food Chem Toxicol. 2022;164:113045.","journal-title":"Food Chem Toxicol"},{"key":"9787_CR123","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jnutbio.2013.11.014","volume":"25","author":"QY Zhang","year":"2014","unstructured":"Zhang QY, Pan Y, Wang R, et al. Quercetin inhibits AMPK\/TXNIP activation and reduces inflammatory lesions to improve insulin signaling defect in the hypothalamus of high fructose-fed rats. J Nutr Biochem. 2014;25:420\u20138.","journal-title":"J Nutr Biochem"},{"key":"9787_CR124","doi-asserted-by":"crossref","unstructured":"Li S, Eguchi N, Lau H, Ichii H. The role of the Nrf2 signaling in obesity and insulin resistance. Int J Mol Sci. 2020;21:6973.","DOI":"10.3390\/ijms21186973"},{"key":"9787_CR125","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.celrep.2017.01.064","volume":"18","author":"Y Yagishita","year":"2017","unstructured":"Yagishita Y, Uruno A, Fukutomi T, et al. Nrf2 improves leptin and insulin resistance provoked by hypothalamic oxidative stress. Cell Rep. 2017;18:2030\u201344.","journal-title":"Cell Rep"},{"key":"9787_CR126","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2337\/db11-0112","volume":"60","author":"DV Chartoumpekis","year":"2011","unstructured":"Chartoumpekis DV, Ziros PG, Psyrogiannis AI, et al. Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes. 2011;60:2465\u201373.","journal-title":"Diabetes"},{"key":"9787_CR127","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1128\/MCB.00677-14","volume":"34","author":"PJ Meakin","year":"2014","unstructured":"Meakin PJ, Chowdhry S, Sharma RS, et al. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol. 2014;34:3305\u201320.","journal-title":"Mol Cell Biol"},{"key":"9787_CR128","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3892\/mmr.2016.5393","volume":"14","author":"Z Liu","year":"2016","unstructured":"Liu Z, Dou W, Ni Z, et al. Deletion of Nrf2 leads to hepatic insulin resistance via the activation of NF-\u03baB in mice fed a high-fat diet. Mol Med Rep. 2016;14:1323\u201331.","journal-title":"Mol Med Rep"},{"key":"9787_CR129","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1172\/JCI67227","volume":"123","author":"NB Ruderman","year":"2013","unstructured":"Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 2013;123:2764\u201372.","journal-title":"J Clin Invest"},{"key":"9787_CR130","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/diabetes.51.7.2199","volume":"51","author":"ES Buhl","year":"2002","unstructured":"Buhl ES, Jessen N, Pold R, et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes. 2002;51:2199\u2013206.","journal-title":"Diabetes"},{"key":"9787_CR131","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cmet.2006.05.005","volume":"3","author":"B Cool","year":"2006","unstructured":"Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;3:403\u201316.","journal-title":"Cell Metab"},{"key":"9787_CR132","doi-asserted-by":"publisher","first-page":"9040","DOI":"10.1021\/acs.jmedchem.7b01344","volume":"60","author":"P Lan","year":"2017","unstructured":"Lan P, Romero FA, Wodka D, et al. Hit-to-lead optimization and discovery of 5-((5-([1,1\u2019-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid (MK-3903): a novel class of benzimidazole-based activators of AMP-activated protein kinase. J Med Chem. 2017;60:9040\u201352.","journal-title":"J Med Chem"},{"key":"9787_CR133","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41589-020-00723-0","volume":"17","author":"Y Liu","year":"2021","unstructured":"Liu Y, Jurczak MJ, Lear TB, et al. A Fbxo48 inhibitor prevents pAMPKalpha degradation and ameliorates insulin resistance. Nat Chem Biol. 2021;17:298\u2013306.","journal-title":"Nat Chem Biol"},{"key":"9787_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.metabol.2017.06.002","volume":"74","author":"J Rheinheimer","year":"2017","unstructured":"Rheinheimer J, de Souza BM, Cardoso NS, et al. Current role of the NLRP3 inflammasome on obesity and insulin resistance: a systematic review. Metabolism. 2017;74:1\u20139.","journal-title":"Metabolism"},{"key":"9787_CR135","doi-asserted-by":"publisher","first-page":"108305","DOI":"10.1016\/j.neuropharm.2020.108305","volume":"180","author":"C Hull","year":"2020","unstructured":"Hull C, Dekeryte R, Buchanan H, et al. NLRP3 inflammasome inhibition with MCC950 improves insulin sensitivity and inflammation in a mouse model of frontotemporal dementia. Neuropharmacology. 2020;180:108305.","journal-title":"Neuropharmacology"},{"key":"9787_CR136","doi-asserted-by":"publisher","first-page":"105885","DOI":"10.1016\/j.phrs.2021.105885","volume":"173","author":"X Chen","year":"2021","unstructured":"Chen X, Zhang D, Li Y, et al. NLRP3 inflammasome and IL-1\u03b2 pathway in type 2 diabetes and atherosclerosis: friend or foe? Pharmacol Res. 2021;173:105885.","journal-title":"Pharmacol Res"},{"key":"9787_CR137","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1007\/s11695-020-04571-8","volume":"30","author":"K Sun","year":"2020","unstructured":"Sun K, Wang J, Lan Z, et al. Sleeve gastroplasty combined with the NLRP3 inflammasome inhibitor CY-09 reduces body weight, improves insulin resistance and alleviates hepatic steatosis in mouse model. Obes Surg. 2020;30:3435\u201343.","journal-title":"Obes Surg"},{"key":"9787_CR138","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1139\/cjpp-2021-0116","volume":"100","author":"PK Chinta","year":"2022","unstructured":"Chinta PK, Tambe S, Umrani D, et al. Effect of parthenolide, an NLRP3 inflammasome inhibitor, on insulin resistance in high-fat diet-obese mice. Can J Physiol Pharmacol. 2022;100:272\u201381.","journal-title":"Can J Physiol Pharmacol"},{"key":"9787_CR139","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41574-021-00551-9","volume":"17","author":"M Kitada","year":"2021","unstructured":"Kitada M, Koya D. Autophagy in metabolic disease and ageing. Nat Rev Endocrinol. 2021;17:647\u201361.","journal-title":"Nat Rev Endocrinol"},{"key":"9787_CR140","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cbin.11015","volume":"42","author":"W Zhou","year":"2018","unstructured":"Zhou W, Ye S. Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy. Cell Biol Int. 2018;42:1282\u201391.","journal-title":"Cell Biol Int"},{"key":"9787_CR141","doi-asserted-by":"publisher","first-page":"689111","DOI":"10.3389\/fphar.2021.689111","volume":"12","author":"D Zhang","year":"2021","unstructured":"Zhang D, Ma Y, Liu J, et al. Metformin alleviates hepatic steatosis and insulin resistance in a mouse model of high-fat diet-induced nonalcoholic fatty liver disease by promoting transcription factor EB-dependent autophagy. Front Pharmacol. 2021;12:689111.","journal-title":"Front Pharmacol"},{"key":"9787_CR142","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature03711","volume":"436","author":"Q Yang","year":"2005","unstructured":"Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356\u201362.","journal-title":"Nature"},{"key":"9787_CR143","doi-asserted-by":"publisher","first-page":"111312","DOI":"10.1016\/j.mce.2021.111312","volume":"531","author":"PA Nono Nankam","year":"2021","unstructured":"Nono Nankam PA, Bluher M. Retinol-binding protein 4 in obesity and metabolic dysfunctions. Mol Cell Endocrinol. 2021;531:111312.","journal-title":"Mol Cell Endocrinol"},{"key":"9787_CR144","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrendo.2009.215","volume":"5","author":"S Prudente","year":"2009","unstructured":"Prudente S, Morini E, Trischitta V. Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol. 2009;5:682\u201393.","journal-title":"Nat Rev Endocrinol"},{"key":"9787_CR145","doi-asserted-by":"publisher","first-page":"e19462","DOI":"10.1371\/journal.pone.0019462","volume":"6","author":"R Di Paola","year":"2011","unstructured":"Di Paola R, Caporarello N, Marucci A, et al. ENPP1 affects insulin action and secretion: evidences from in vitro studies. PLoS ONE. 2011;6:e19462.","journal-title":"PLoS ONE"},{"key":"9787_CR146","doi-asserted-by":"publisher","first-page":"1026246","DOI":"10.3389\/fphar.2022.1026246","volume":"13","author":"B Yang","year":"2022","unstructured":"Yang B, Xin M, Liang S, et al. New insight into the management of renal excretion and hyperuricemia: potential therapeutic strategies with natural bioactive compounds. Front Pharmacol. 2022;13:1026246.","journal-title":"Front Pharmacol"},{"key":"9787_CR147","doi-asserted-by":"crossref","unstructured":"Zhang X, Nie Q, Zhang Z et al. Resveratrol affects the expression of uric acid transporter by improving inflammation. Mol Med Rep. 2021;24:564.","DOI":"10.3892\/mmr.2021.12203"},{"key":"9787_CR148","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jpba.2017.02.048","volume":"139","author":"M Sang","year":"2017","unstructured":"Sang M, Du G, Hao J, et al. Modeling and optimizing inhibitory activities of Nelumbinis folium extract on xanthine oxidase using response surface methodology. J Pharm Biomed Anal. 2017;139:37\u201343.","journal-title":"J Pharm Biomed Anal"},{"key":"9787_CR149","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.biopha.2018.12.039","volume":"110","author":"K Xu","year":"2019","unstructured":"Xu K, Liu S, Zhao X, et al. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. Biomed Pharmacother. 2019;110:844\u20139.","journal-title":"Biomed Pharmacother"},{"key":"9787_CR150","doi-asserted-by":"publisher","first-page":"913378","DOI":"10.3389\/fphar.2022.913378","volume":"13","author":"S Yang","year":"2022","unstructured":"Yang S, Cao S, Li C, et al. Berberrubine, a main metabolite of berberine, alleviates non-alcoholic fatty liver disease via modulating glucose and lipid metabolism and restoring gut microbiota. Front Pharmacol. 2022;13:913378.","journal-title":"Front Pharmacol"},{"key":"9787_CR151","doi-asserted-by":"publisher","first-page":"5618","DOI":"10.1021\/acs.jafc.1c01109","volume":"69","author":"YJ Zhou","year":"2021","unstructured":"Zhou YJ, Xu N, Zhang XC, et al. Chrysin improves glucose and lipid metabolism disorders by regulating the AMPK\/PI3K\/AKT signaling pathway in insulin-resistant HepG2 cells and HFD\/STZ-induced C57BL\/6J mice. J Agric Food Chem. 2021;69:5618\u201327.","journal-title":"J Agric Food Chem"},{"key":"9787_CR152","doi-asserted-by":"crossref","unstructured":"Kim SM, Imm JY. The effect of chrysin-loaded phytosomes on insulin resistance and blood sugar control in type 2 diabetic db\/db mice. Molecules. 2020;25:550325.","DOI":"10.3390\/molecules25235503"},{"key":"9787_CR153","doi-asserted-by":"crossref","unstructured":"Chang YH, Chiang YF, Chen HY et al. Anti-inflammatory and anti-hyperuricemic effects of chrysin on a high fructose corn syrup-induced hyperuricemia rat model via the amelioration of urate transporters and inhibition of NLRP3 inflammasome signaling pathway. Antioxidants (Basel). 2021;10:564.","DOI":"10.3390\/antiox10040564"},{"key":"9787_CR154","doi-asserted-by":"publisher","first-page":"113044","DOI":"10.1016\/j.jep.2020.113044","volume":"260","author":"W Liu","year":"2020","unstructured":"Liu W, Chen X, Ge Y, et al. Network pharmacology strategy for revealing the pharmacological mechanism of pharmacokinetic target components of San-Ye-Tang-Zhi-Qing formula for the treatment of type 2 diabetes mellitus. J Ethnopharmacol. 2020;260:113044.","journal-title":"J Ethnopharmacol"},{"key":"9787_CR155","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00394-020-02414-x","volume":"60","author":"Y Guo","year":"2021","unstructured":"Guo Y, Yu Y, Li H, et al. Inulin supplementation ameliorates hyperuricemia and modulates gut microbiota in Uox-knockout mice. Eur J Nutr. 2021;60:2217\u201330.","journal-title":"Eur J Nutr"},{"key":"9787_CR156","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.mam.2012.11.001","volume":"34","author":"J Shen","year":"2013","unstructured":"Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013;34:39\u201358.","journal-title":"Mol Aspects Med"},{"key":"9787_CR157","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","volume":"23","author":"A Agus","year":"2018","unstructured":"Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23:716\u201324.","journal-title":"Cell Host Microbe"},{"key":"9787_CR158","first-page":"283","volume":"31","author":"MJ Saad","year":"2016","unstructured":"Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiol (Bethesda). 2016;31:283\u201393.","journal-title":"Physiol (Bethesda)"},{"key":"9787_CR159","doi-asserted-by":"publisher","first-page":"761757","DOI":"10.3389\/fcimb.2021.761757","volume":"11","author":"W Zhang","year":"2021","unstructured":"Zhang W, Wang T, Guo R, et al. Variation of serum uric acid is associated with gut microbiota in patients with Diabetes Mellitus. Front Cell Infect Microbiol. 2021;11:761757.","journal-title":"Front Cell Infect Microbiol"},{"key":"9787_CR160","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3389\/fphar.2019.01193","volume":"10","author":"Z Su","year":"2019","unstructured":"Su Z, Nie Y, Huang X, et al. Mitophagy in hepatic insulin resistance: therapeutic potential and concerns. Front Pharmacol. 2019;10:1193.","journal-title":"Front Pharmacol"},{"key":"9787_CR161","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm3984","volume":"16","author":"PM Quir\u00f3s","year":"2015","unstructured":"Quir\u00f3s PM, Langer T, L\u00f3pez-Ot\u00edn C. New roles for mitochondrial proteases in health, ageing and disease. Nat Rev Mol Cell Biol. 2015;16:345\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9787_CR162","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.mam.2018.11.001","volume":"66","author":"R Villalobos-Labra","year":"2019","unstructured":"Villalobos-Labra R, Subiabre M, Toledo F, et al. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. Mol Aspects Med. 2019;66:49\u201361.","journal-title":"Mol Aspects Med"},{"key":"9787_CR163","doi-asserted-by":"crossref","unstructured":"Ouyang R, Zhao X, Zhang R et al. FGF21 attenuates high uric acid\u2013induced endoplasmic reticulum stress, inflammation and vascular endothelial cell dysfunction by activating Sirt1. Mol Med Rep. 2022;25:35.","DOI":"10.3892\/mmr.2021.12551"},{"key":"9787_CR164","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1159\/000488048","volume":"45","author":"M Yan","year":"2018","unstructured":"Yan M, Chen K, He L, et al. Uric acid induces cardiomyocyte apoptosis via activation of calpain-1 and endoplasmic reticulum stress. Cell Physiol Biochem. 2018;45:2122\u201335.","journal-title":"Cell Physiol Biochem"},{"key":"9787_CR165","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/labinvest.2014.98","volume":"94","author":"YJ Choi","year":"2014","unstructured":"Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94:1114\u201325.","journal-title":"Lab Invest"},{"key":"9787_CR166","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/nep.12127","volume":"18","author":"S Li","year":"2013","unstructured":"Li S, Zhao F, Cheng S, et al. Uric acid-induced endoplasmic reticulum stress triggers phenotypic change in rat glomerular mesangial cells. Nephrol (Carlton). 2013;18:682\u20139.","journal-title":"Nephrol (Carlton)"},{"key":"9787_CR167","doi-asserted-by":"crossref","unstructured":"Ebrahimi R, Pasalar P, Shokri H et al. Evidence for the effect of soluble uric acid in augmenting endoplasmic reticulum stress markers in human peripheral blood mononuclear cells. J Physiol Biochem. 2022;78:343\u201353.","DOI":"10.1007\/s13105-021-00869-y"},{"key":"9787_CR168","doi-asserted-by":"publisher","first-page":"520","DOI":"10.7150\/ijbs.8879","volume":"10","author":"YC Liu","year":"2014","unstructured":"Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. Int J Biol Sci. 2014;10:520\u20139.","journal-title":"Int J Biol Sci"},{"key":"9787_CR169","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425\u201340.","journal-title":"J Cell Physiol"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-023-09787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-023-09787-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-023-09787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T20:27:23Z","timestamp":1701808043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-023-09787-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":169,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["9787"],"URL":"https:\/\/doi.org\/10.1007\/s11154-023-09787-4","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"10 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors read and approve the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}